- Home
- KURA
KURA
Kura Oncology Inc.
as 04-23-2025 1:38pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 592.7M | IPO Year: | N/A |
| Target Price: | $25.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $23.48 | Next Earning Date: | 05-01-2025 |
| Revenue: | $53,883,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 44.32% | Revenue Growth (next year): | 173.73% |
Stock Insider Trading Activity of Kura Oncology Inc. (KURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hasnain Faheem | KURA | Director | Mar 21 '25 | Sell | $8.00 | 22,682 | $181,456.00 | 23,983 | |
| Bair Teresa Brophy | KURA | Chief Legal Officer | Jan 28 '25 | Sell | $7.87 | 7,281 | $57,315.30 | 107,948 | |
| DOYLE THOMAS JAMES | KURA | SVP, Finance & Accounting | Jan 28 '25 | Sell | $7.87 | 4,949 | $38,958.03 | 88,193 | |
| FORD KATHLEEN | KURA | Chief Operating Officer | Jan 28 '25 | Sell | $7.87 | 1,817 | $14,303.24 | 21,367 | |
| Powl Brian T. | KURA | Chief Commercial Officer | Jan 28 '25 | Sell | $7.87 | 1,583 | $12,461.22 | 59,667 | |
| Leoni Mollie | KURA | Chief Medical Officer | Jan 28 '25 | Sell | $7.87 | 4,963 | $39,068.24 | 89,610 | |
| Burrows Francis | KURA | Chief Scientific Officer | Jan 28 '25 | Sell | $7.87 | 2,166 | $17,050.54 | 20,705 |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
Kura Oncology Submits Ziftomenib NDA to FDA for Treating Acute Myeloid Leukemia
GlobeNewswire
15 days ago
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
GlobeNewswire
19 days ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
22 days ago
Kura Oncology to Participate in Stifel Targeted Oncology Forum
GlobeNewswire
a month ago
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
GlobeNewswire
2 months ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating
Simply Wall St.
2 months ago
Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.